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Antimicrobial peptides (AMPs) are molecules from
innate immunity with high potential as novel anti-
infective agents. Most of them inactivate bacteria
through pore formation or membrane barrier disrup-
tion, but others cross the membrane without
damages and act inside the cells, affecting vital
processes. However, little is known about their intra-
cellular bacterial targets. Here we report that
Bac71-35, a proline-rich AMP belonging to the catheli-
cidin family, can reach high concentrations (up to
340mM) inside theE. colicytoplasm.Thepeptidespe-
cifically and completely inhibits in vitro translation in
the micromolar concentration range. Experiments of
incorporation of radioactive precursors inmacromol-
ecules with E. coli cells confirmed that Bac71-35 af-
fects specifically protein synthesis. Ribosome copre-
cipitation and crosslinking assays showed that the
peptide interacts with ribosomes, binding to a limited
subset of ribosomal proteins. Overall, these results
indicate that the killing mechanism of Bac71-35 is
based on a specific block of protein synthesis.
INTRODUCTION
Antimicrobial peptides (AMPs) are ancient and widespread
effectors of innate immunity in higher eukaryotes, including ani-
mals and plants, in which they act as a first line of defense
against pathogen infection (Diamond et al., 2009; Lai and Gallo,
2009). AMPs aremultifunctional molecules. Besides their capac-
ity to directly kill microbes, they also exert immunomodulatory
activity on the host (Lai and Gallo, 2009). Because of their broad
activity spectrum and modest size, AMPs are currently being
considered as potential alternatives or enhancers for antibiotics
to help overcome the worsening problem of the emergence of
multidrug-resistant bacteria (Brogden and Brogden, 2011;
Nguyen et al., 2011). Despite their great molecular diversity,
most AMPs show amphipathic a-helical or b sheet conforma-
tions suitable for a selectivemembrane-interacting activity, lead-
ing to a lethal disruption of the microbial envelope (Epand andChemistry & Biology 21, 1639–164Vogel, 1999). However, some AMPs affect microbial viability by
mechanisms involving interaction with intracellular targets
(Hale and Hancock, 2007; Nicolas, 2009). Several AMPs may
recognize and inactivate cellular targets in vitro, such as nucleic
acids, proteins, and enzymes (Nicolas, 2009), and their mode of
action is assumed to be mediated by translocation across the
plasma membrane in a nonlethal manner. However, a strict
connection between binding to internal structures of the cells
and antimicrobial activity has not yet been demonstrated. In
addition, the precise concentration reached by the AMPs inside
the bacterial cells remains elusive.
The group of proline-rich AMPs (PR-AMPs) is an example of
nonmembranolytic peptides (Cudic and Otvos, 2002; Scocchi
et al., 2011). PR-AMPs are present in many mammalian neutro-
phils (Scocchi et al., 2011) as well as in the hemolymph of several
species of insects and crustaceans (Otvos, 2002). PR-AMPs
share a positive charge mainly due to arginine residues, and
they have a high content of proline residues, which confers an
extended conformation (Scocchi et al., 2011). Insect and
mammalian proline-rich peptides are most active against
Gram-negative bacteria, show low cytotoxicity toward eukary-
otic cells, and share also a similar mode of bacterial cell internal-
ization. Bac71-35, a fully active N-terminal fragment of Bac7
(Benincasa et al., 2004) is actively transported into E. coli cells
by a mechanism involving the inner membrane protein SbmA
(Mattiuzzo et al., 2007). Mutants lacking this protein show
decreased susceptibility to many mammalian and insect PR-
AMPs (Mattiuzzo et al., 2007; Narayanan et al., 2014; Pra¨nting
et al., 2008). In addition, Bac71-35 also possesses the capacity
to translocate into eukaryotic cells without cell damaging (Tom-
asinsig et al., 2006). The molecular chaperone DnaK has been
proposed to be a cytoplasmic target for insect PR-AMPs (Kragol
et al., 2001). However, the in vivo importance of DnaK inhibition
remains controversial. Because E. coli DDnaK strains are still
susceptible to these peptides (Czihal et al., 2012; Scocchi
et al., 2009), this suggests that other intracellular targets of PR-
AMPs are likely to exist. On the other hand, it has been shown
that sublethal concentrations of Bac71-35 are able to profoundly
modify the transcriptional profile of E. coli cells (Tomasinsig
et al., 2004). A number of genes involved in transcription, trans-
lation, or both were among the upregulated genes, suggesting
that the peptide could affect one of these processes.
In this study, we investigated the intracellular mechanism of
action of the proline-rich peptide Bac71-35 and compared it7, December 18, 2014 ª2014 Elsevier Ltd All rights reserved 1639
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Figure 1. Intracellular Concentration of Radioactive Bac71-35Alch
14C
in Intact E. coli Cells
(A) Radioactivity of different bacterial fractions treated with the peptide.
BW25113 cells were exposed to 10 mM peptide for 10 min. The bacterial
suspension was centrifuged, and the radioactivity of supernatant and pellet
was measured before and after washings. A peptide-untreated culture was
used for the blank. A representative result of radioactivity decrease due to
pellet washing is shown in the inset. Error bars represent SD.
(B) Permeabilization assay on BW25113 E. coli cells. Bacteria were exposed in
MH broth to 1 and 10 mM Bac71-35 for 10 and 30 min in the presence of pro-
pidium iodide and analyzed by flow cytometry.
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Bac71-35 Inhibits Bacterial Protein Synthesiswith other cathelicidins that are not rich in proline residues. We
determined the effective concentrations reached by Bac71-35 in-
side E. coli cells. By using in vitro transcription and transcription/
translation systems and by evaluating the cellular incorporation
of macromolecule precursors, we identified protein synthesis
as a major target of the peptide. In line with that, we showed
that the peptide alone is able to bind to 70S ribosomes in vitro.
We thus propose a model in which AMPs act inside the cell by
interacting with ribosomes, leading to protein synthesis inhibi-
tion. These results are of interest to design new drugs with
antibiotic activity based on the mechanism of action of this
proline-rich peptide.1640 Chemistry & Biology 21, 1639–1647, December 18, 2014 ª2014RESULTS
Bac71-35 Is Concentrated inside the E. coli Cell
Cytoplasm
We calculated the intracellular concentration reached by
Bac71-35 inside E. coli cells (Figure 1). The radioactive derivative
of Bac7, Bac71-35Alch
14C, was incubated with bacteria at 10 mM,
a concentration that does not permeabilize the cell membranes
(Figure 1B). The radioactivity of the supernatant and the bacterial
pellet was measured after extensive washing with high-salt
buffer. We found that a significant amount (6%) of the radioac-
tivity was strongly associated with the washed bacterial pellet
(Figure 1A). We assumed that this pellet-associated radioactivity
is localized in the cytosol because we previously demonstrated
by immunogold electron microscopy that Bac71-35 is nearly
exclusively accumulating in the E. coli cytosol (Podda et al.,
2006). Taking into account the ratio between the cell volume
and the total culture volume, we estimated that the peptide
reached an intracellular concentration of 340 mM inside the
E. coli cells. This result is in agreement with the energy-driven
translocation of Bac71-35 through the inner membrane SbmA
protein (Runti et al., 2013) and is likely sufficient to interact with
intracellular structures.
Bac71-35 Inhibits the Transcription/Translation Process
In vitro transcription/translation assays were performed to eval-
uate any inhibitory activity exerted by Bac71-35 on one or both of
these processes, as previously suggested (Tomasinsig et al.,
2004). Increasing amounts of Bac71-35 were added to reactions
in an in vitro transcription/translation assay, and the inhibitory
effect of the peptide was evaluated by the level of a luciferase re-
porter estimated by SDS-PAGE protein bands and by the lumi-
nescence intensity resulting from luciferase activity. At 1 mM,
Bac71-35 already exerted a strong inhibition of the luciferase ac-
tivity (80%), which was completed at 50 mM peptide (Figures 2A
and 2B). The inhibition thus takes place in a concentration-
dependentmanner and at concentrationsmuch lower than those
that can be reached by the peptide inside the bacterial
cytoplasm.
We repeated the assay with different types of AMPs to assess
the specificity of the inhibition. The cathelicidins LL-37 and
BMAP-27 were chosen because their size, net charge, and anti-
microbial potency (minimal inhibitory concentration [MIC] =
1–5 mM) are similar to those of the proline-rich peptide (Podda
et al., 2006; Skerlavaj et al., 1996; Zelezetsky et al., 2006), while
on the other hand they have unrelated structure and a different
mechanism of action that is based on membrane damage
(Zanetti et al., 2000).We found that both LL-37 and BMAP-27
at 50 mM only slightly inhibited the synthesis of luciferase, to
less than 50% reduction compared with the untreated control
(Figures 2C and 2D). In contrast, the protein synthesis inhibitor
kanamycin at 50 mM completely inhibited the activity of lucif-
erase (Figures 2C and 2D).
Interaction of Bac71-35 with DNA Cannot Explain Its
Specific Inhibition on Transcription/Translation
To determine whether the inhibitory effect of Bac71-35 on tran-
scription/translation was due to its electrostatic interaction with
nucleic acids, we evaluated the in vitro capability of Bac71-35Elsevier Ltd All rights reserved
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Figure 2. In Vitro Transcription/Translation
Assay in the Presence of Bac71-35
(A and B) Synthesis of the reporter luciferase
incubated without (Ctrl+) or with Bac71-35 was
evaluated by SDS-PAGE (A) and by luminescence
intensity, shown as percentage of the positive
control (100%) (B).
(C and D) Synthesis of the reporter luciferase
incubated without (Ctrl+) or with 50 mM LL-37,
BMAP-27, and kanamycin (Kan) was evaluated by
SDS-PAGE (C) and by luminescence intensity (D).
As negative control, reactions without the lucif-
erase-encoding DNA (Crtl-) were used.
(E) DNA-AMP interaction assay. Increasing
amounts of Bac71-35, LL-37, and BMAP-27 were
coincubated with linearized pBluescript SK+
plasmid and separated on agarose gel.
(F) In vitro transcription assay in the presence of
Bac71-35. RNA synthesis in absence (Ctrl+) or
presence of 50 mM Bac71-35, LL-37, BMAP-27, or
kanamycin (Kan) shown as percentage of a posi-
tive control sample (100%). A reaction without
DNA template (pGEM) was used as a negative
control (Ctrl-). Error bars represent SD.
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Bac71-35 Inhibits Bacterial Protein Synthesisto bind DNA. An electrophoretic mobility shift assay was per-
formed on plasmid DNA in the presence of the Bac71-35, LL-
37, and BMAP-27 peptides. Each peptide was incubated
with the same amount of linearized plasmid using a buffer
approximating the salt and protein concentration of the bacterial
cytosol (Park et al., 1998). Over a range of peptide concentra-
tions of 0.75 to 2.5 mM, all the AMPs used retained DNA in the
agarose wells, consistent with a peptide-induced precipitation
of the nucleic acid. Thus, a similar plasmid retardation pattern
was observed with all the peptides at high concentration, and
no specific effect was detected using Bac71-35 (Figure 2E).
This behavior suggests that unspecific electrostatic interactions
occurred between the negatively charged DNA and each of the
cationic AMPs, regardless of their identity. Thus the specific in-
hibition of transcription/translation by Bac71-35 and not by LL-
37 and BMAP-27 cannot be explained only by its DNA-binding
activity.
Bac71-35 Does Not Affect Transcription
To understand whether Bac71-35 inhibits transcription, transla-
tion, or both, we performed an in vitro transcription assay in
the presence of the peptide or the two other cathelicidin AMPs
used above. After the in vitro transcription reaction, the newly
synthesized RNA was purified and quantified with a Bioanalyzer.
No dramatic reduction in the amount of RNA (<30%) was
observed in the presence of 50 mM Bac71-35, indicating that
the peptide did not strongly interfere with transcription even at
high concentrations (Figure 2F). Unexpectedly, the LL-37 pep-
tide at 50 mM inhibited transcription in a remarkable manner,
while BMAP-27 did not show any appreciable effect.
Bac71-35 Specifically Inhibits Protein Synthesis in E. coli
Cells
In order to verify the in vivo effects of Bac71-35 on protein synthe-
sis and/or RNA transcription and DNA replication, we measured
the incorporation of radioactive leucine, uridine, and thymidine,Chemistry & Biology 21, 1639–164respectively, in protein, RNA, and DNA within bacterial cells
treated with the peptide. BW25113 E. coli cells were incubated
with 1 mM Bac71-35, a concentration that is in the range of the
MIC of Bac71-35 against this strain. After exposure to the peptide,
bacteria showed an important decrease only in the incorporation
of 3H-leucine (Figure 3A). This effect was indistinguishable from
that shown by kanamycin, an aminoglycoside known to bind the
30S subunit of ribosomes and to inhibit protein synthesis.
Conversely, the incorporation of radioactive 3H-thymidine and
3H-uridine did not show any notable decrease compared with
the untreated controls, while the antibiotics nalidixic acid and
rifampicin, respectively, inhibited DNA and RNA synthesis, in
agreement with their known inhibitory activities (Figures 3B
and 3C). These results strongly indicate that only protein synthe-
sis is affected by Bac71-35, confirming the specific inhibition of
translation observed in vitro.
The SbmA protein is an inner membrane transporter involved
in the uptake of Bac71-35 into bacterial cells. sbmA null mutant
strains showed a reduced internalization and decreased suscep-
tibility to this peptide (Mattiuzzo et al., 2007). We found that the
E. coli BW25113 DsbmA strain treated with 1 mM Bac71-35
showed a higher level of 3H-leucine incorporation compared
with the similarly treated wild-type strain, indicating that the inhi-
bition of protein synthesis by Bac71-35 is dependent on its inter-
nalization (Figure 3D).
Bac71-35 Cosediments with Purified Ribosomes
The previous results suggested translation as Bac71-35 target in
bacteria, so we hypothesized that ribosomes could be involved
in its mechanism of action. Therefore, we checked whether
Bac71-35 can bind directly to them. We incubated purified 70S
E. coli ribosomes with increasing amounts of purified Bac71-35
and separated ribosome-bound Bac71-35 by pelleting ribosomes
through ultracentrifugation. The presence of Bac71-35 in the ribo-
somal pellet fraction was analyzed by immunoblots using spe-
cific antiserum against the peptide. After centrifugation, we7, December 18, 2014 ª2014 Elsevier Ltd All rights reserved 1641
Figure 3. Incorporation of Radioactive Pre-
cursors in Macromolecules in Bac71-35-
Treated E. coli BW25113
(A) Incorporation of 3H-leucine in an untreated cul-
ture (diamonds), in the presence of 1 mM Bac71-35
(squares), or 200 mM kanamycin (crosses).
(B) Incorporation of 3H-thymidine in an untreated
culture (diamonds), in thepresenceof1mMBac71-35
(squares), or 100 mM nalidixic acid (crosses).
(C) Incorporation of 3H-uridine in an untreated
culture (diamonds), in the presence of 1 mM
Bac71-35 (squares), or 100 mM rifampicin (crosses).
(D) Incorporation of 3H-leucine in BW25113
DsbmA untreated cells (diamonds) and in the
presence of 1 mM Bac71-35 (triangles), or in wild-
type BW25113 in the presence of 1 mM Bac71-35
(squares).
Black arrows indicate the time of addition of the
radioactive precursor; white arrows indicate the
addition of the antimicrobial peptide (where
the arrow is not shown, the antimicrobial com-
pound was added 20 min before the labeled pre-
cursor). Differences in timing were due to the
different physiologic incorporation rate of the
precursors. Error bars represent SD.
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Bac71-35 Inhibits Bacterial Protein Synthesisfound Bac71-35 in the pellet fraction only in the presence of ribo-
somes (Figure 4A), which suggests a direct interaction between
Bac71-35 and the ribosome. This interaction was not disrupted
after washing the pellet fraction with salt-solution, indicating
that this association is not only dependent on charge interac-
tions. In addition, increasing concentration of Bac71-35 in the
binding reaction resulted in a complete saturation of the binding
when 20-fold molar excess of Bac71-35 was used (Figure 4B),
which suggests that there is one or multiple specific Bac71-35-
binding sites on the ribosome. We calculated that the apparent
dissociation constant for the Bac71-35-ribosome complex is in
themicromolar range (6 mM), a value of the same order as other
ribosomal binding factors (Kudva et al., 2013).
To evaluate the specificity of the peptide-ribosome interac-
tion, purified, nontranslating ribosomes were incubated in the
presence of Bac71-35BPA20, a photocrosslinkable derivative of
Bac71-35. Western blot analysis of the peptide-treated ribo-
somes using an anti-Bac7 antibody showed two major high-mo-
lecular weight bands crosslinked to Bac71-35 (Figure 4C) among
the whole ribosomal protein set. These bands have apparent
molecular weights of20 and30 kDa, indicating that a specific
binding occurred with ribosomal proteins of 16 and 26 KDa.
Taken together, our findings show that Bac71-35 associates
with ribosomes by binding specific ribosomal proteins, and we
propose that this association is responsible for the reduced pro-
tein synthesis inducedby thepeptide in vitroand in livingbacteria.
DISCUSSION
Data concerning the activity of AMPs on molecular targets other
than the cytoplasmic membrane are scarce and incomplete, and
the killing mechanisms of non-membrane-disrupting peptides
remain largely unknown. In this study, we demonstrate that the
AMP Bac71-35 is able to accumulate at high concentrations in-
side the target bacteria and to specifically inhibit protein synthe-
sis in the micromolar concentration range, probably by binding1642 Chemistry & Biology 21, 1639–1647, December 18, 2014 ª2014to ribosomes. This mode of action has previously been postu-
lated for other AMPs (Hale and Hancock, 2007; Nicolas, 2009),
but this study clearly demonstrated that inhibition of protein syn-
thesis is the killing mechanism for an AMP.
In contrast to most AMPs that have the membrane as main
target, PR-AMPs and some other AMPs (Nicolas, 2009) pene-
trate into the Gram-negative bacteria without damaging the
membrane. For example, it has been shown by immunogold
electron microscopy that the Bac71-35 peptide is present in the
bacterial cytosol without causing notable membrane damage
(Podda et al., 2006). Despite that, the concentration reached
intracellularly by these peptides has remained undetermined
so far. Here we show that Bac71-35 added to a E. coli culture at
a concentration that does not perturb the membrane (10 mM)
(Benincasa et al., 2009; Podda et al., 2006) is more than 30-
fold enriched in the cells, reaching a concentration close to
0.34 mM, which represents thus the effective amount of peptide
acting on its bacterial internal target(s). The extent of accumula-
tion is in agreement with an active import mechanism already
described for some PR-AMPs dependent on the SbmA protein
(Mattiuzzo et al., 2007; Runti et al., 2013). In addition, other fac-
tors may contribute to increase the intracellular peptide concen-
tration. The peptide, once in the cytoplasm, is likely sequestered
by macromolecular cell components such as nucleic acids or
protein complexes (Scocchi et al., 2009), and this can drive the
further uptake of the peptide.
The processes of transcription, translation, or both were
considered plausible candidates as possible intracellular targets
of Bac71-35. In addition to the fact that several genes linked to
these processes were found upregulated after exposure of
E. coli cells to sublethal amounts of Bac71-35 (Tomasinsig
et al., 2004), it seemed reasonable that a highly cationic peptide
could bind the negatively charged nucleic acids or that it could
be electrostatically attracted by the nucleoid, where the tran-
scription and the translation take place. The in vitro experiments
of coupled transcription/translation indicated that the peptideElsevier Ltd All rights reserved
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Figure 4. The Bac71-35 Peptide Binds Bacterial Ribosomes
Binding of Bac71-35 peptide to E. coli 70S ribosomes was analyzed by cose-
dimentation assays using increasing concentrations of peptide and 1 mM
ribosomes.
(A) Ribosomal pellets were analyzed by immune blotting using an anti-Bac7
antiserum. Representative immunoblots are shown.
(B) Signals from immunoblot as in (A) were quantified. The solid line is a fit of the
theoretical Michaelis-Menten equation to the data set. a.u., arbitrary units.
(C) Ponceau red staining (left) and western blot using an a-Bac71-35 antibody
(right) after SDS-PAGE separation of 1 mM ribosomes incubated with 10 mM
Bac71-35BPA20 and UV crosslinked. An additional band (asterisk) is visible in
the control with Bac71-35BPA20 only, because in the absence of the reducing
agent TCEP, the peptide forms dimers (C). Error bars represent SD.
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Bac71-35 Inhibits Bacterial Protein Synthesisstrongly inhibits the whole process at considerably lower con-
centrations than those intracellularly reached by Bac71-35,
(80% inhibition at 1 mM). Most important, the inhibition of tran-
scription/translation is a specific effect of Bac71-35. The a-helical
cationic cathelicidins, LL-37 and BMAP-27, resembling Bac71-35
respectively in the number of amino acid residues, positive
charges, and antimicrobial activity did not affect the transcrip-
tion/translation processes in a comparable manner, indicating
that a specific effect of the peptide occurs, not simply an unspe-
cific ‘‘interference’’ due to cationic nature of the peptide.
Cationic AMPs could have an unspecific bactericidal effect
due to their ability to interact with nucleic acids. Although weChemistry & Biology 21, 1639–164found that Bac71-35 binds to DNA, LL-37 and BMAP-27 also
do so and to a comparable extent. The same binding property
has been previously observed with several different AMPs,
such as indolicidin, tachyplesin, and buforin II (Hsu et al., 2005;
Park et al., 1998), but a connection between DNA binding and in-
hibition of vital processes has not yet been demonstrated for
these peptides (Nicolas, 2009). It seems likely that interactions
between AMPs and DNA are due to electrostatic attraction be-
tween the positively charged peptide and the phosphate groups
of the nucleic acid. In the DNA-peptide interaction experiments,
we observed the precipitation of DNA at peptide concentrations
corresponding to a 2:1 peptide/DNA ratio (w/w). This result sug-
gests that Bac71-35 can bind and aggregate DNA when its
amount is twofold than that of the nucleic acid. Because of the
amount of nucleic acids in a single bacterial cell, estimated at
z64 fg (Neidhardt, 1996), and the amount of Bac71-35 calculated
as 9 fg for a single bacterium in our experiments, the peptide
concentration is far too low to reach the peptide/DNA ratio
required for DNA aggregation. In contrast, transcription/transla-
tion inhibition occurs with amounts of peptide much lower than
those needed to effectively interact with DNA. Taken together,
these results indicate that the inhibiting activity of Bac71-35 on
the transcription/translation processes cannot be simply ex-
plained as a ‘‘disturbing activity’’ caused by binding of the pep-
tide to DNA, eventually followed by DNA aggregation. Results of
transcription inhibition assays and in vivo incorporation of radio-
active precursors are in agreement with a specific action on pro-
tein synthesis only, while DNA or RNA synthesis is not affected.
Moreover, the dependence of in vivo protein synthesis inhibition
by Bac71-35 on the presence of SbmA transporter, and thus pep-
tide import, is consistent with one or several intracellular targets
of the peptide. In line with that, it was recently shown that
nodule-specific cysteine-rich (NCR) peptides, produced in rhizo-
bium-infected plant cells and having antimicrobial activity, pene-
trate bacteria and form complexes with many bacterial proteins
(Farkas et al., 2014). Moreover, the LL-37 and BMAP-27 did not
block protein synthesis in the coupled transcription/translation
assay. Surprisingly, the LL-37 peptide showed a strong inhibitory
activity on in vitro transcription. We hypothesize that, because
this peptide is known to form aggregates and to be ‘‘sticky’’ (Ze-
lezetsky et al., 2006), it could bind to RNA polymerase, reducing
its activity. Synthesis of RNA in the presence of LL-37 was
reduced but not completely blocked. It is thus possible that a
sufficient amount of RNA is produced in the presence of LL-37
to fully support protein synthesis in the in vitro transcription/
translation assay.
Our data on the incorporation of precursors in viable bacterial
cells differ for some aspects from those reported previously by
Skerlavaj et al. (1990). In that study, it was observed that the
native Bac7 peptide (60 residues in length) inhibited the synthe-
sis of both RNA and protein, while at the same time causing
membrane permeabilization. The authors proposed a lyticmech-
anism of action for Bac7, which indirectly affected protein and
RNA synthesis. Similarly Boman et al. (1993) proposed that
PR-39, a different PR-AMP, stopped protein and DNA synthesis.
However, both studies used the native complete form of the pep-
tides at concentrationsmuch higher than those corresponding to
the respective MIC values. It is known that these PR-AMP pep-
tides, when applied at high concentrations and especially in their7, December 18, 2014 ª2014 Elsevier Ltd All rights reserved 1643
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Bac71-35 Inhibits Bacterial Protein Synthesislonger native form, can also exert a concurrent membrane per-
meabilizing effect (Podda et al., 2006). Under these conditions,
inhibition of protein andRNA synthesis results from an unspecific
and indirect effect due to a remarkable membrane damage.
The cosedimentation of Bac71-35 with ribosomes shown here
and the crosslinking of the peptide to specific ribosomal proteins
suggest that the AMP inhibits specific subunits of the ribosome
or ribosome-associated proteins. The molecular chaperone
DnaK has been proposed as a primary molecular target for
several PR-AMPs, such as the insect apidaecins and pyrrhocor-
icin (Kragol et al., 2001). Also, Bac71-35 was shown to directly
interact with and to inhibit in vitro the activity of this chaperone
protein. However, E. coli DDnaK strains are still susceptible to
the peptide (Scocchi et al., 2009) and to the apidaecin derivative
Api88 (Czihal et al., 2012), suggesting that other crucial intracel-
lular targets of Bac71-35 and of other PR-AMPs should exist.
DnaK, the major bacterial Hsp70, functions as a central hub in
the E.coli chaperone network (Castanie´-Cornet et al., 2014).
Interestingly, DnaK and its DnaJ cochaperone cooperate with
the upstream ribosome-associated trigger factor (TF) and the
downstream GroEL to assist folding of newly synthesized poly-
peptides. Upon deletion of TF, a significant increase of the num-
ber of newly synthesized polypeptides interacting with DnaK has
been shown in vivo, including ribosomal and small basic proteins
(Calloni et al., 2012), supporting a functional redundancy be-
tween these two chaperones. The discovery that Bac71-35 spe-
cifically inhibits protein synthesis in viable E. coli cells and that
this peptide is able to interact in vitro with purified nontranslating
ribosomes with an affinity comparable to that of other cotransla-
tional factors leads us to propose a model for the intracellular
molecular mechanism by which Bac71-35 acts on bacteria. We
suggest that it could block protein synthesis by targeting the ri-
bosomes, binding specific ribosomal proteins, and thus possibly
preventing further cotranslational events (e.g., interaction of co-
translational chaperones with ribosomes) necessary to ensure
translation of any polypeptide chain. It will be interesting in the
future to identify the molecular identity of the ribosomal proteins
bound by the peptide and so to exactly determine its ribosomal
docking region. This informationwill be important to shed light on
the possible interplay of the peptides with other essential co-
translation factors and will have implications in the field of
biomedicine. Indeed, protein synthesis and the ribosomes are
the targets of many conventional antibiotics. Thus, one of the
possible outcomes of understanding the details of interaction
between Bac71-35 and ribosomes will be a unique opportunity
to use this peptide as a starting point to design new molecules
that inhibit bacterial ribosomes, leading to the development of
novel and effective antibiotic drugs. Alternative antibiotics to
those currently available are urgently required because multi-
drug resistance in pathogenic bacteria has been rising enor-
mously in recent decades.
SIGNIFICANCE
The emergence and spread of antibiotic-resistant patho-
gens and the urgent need for new antimicrobial drugs have
revived interest in molecules with alternative modes of
combating them. This work clarifies the molecular mecha-
nism of action of Bac7, a PR-AMP of natural origin, showing1644 Chemistry & Biology 21, 1639–1647, December 18, 2014 ª2014that it kills bacteria by selectively inhibiting protein synthe-
sis, likely interacting with specific ribosomal proteins. A
vast number of antimicrobial peptides have been described
and their antibacterial properties reported, but information
on their modes of action often remains fragmentary. Bac7
is a rare example for which the killing mechanism is
described in detail, including the previously described pro-
tein transporter required for its translocation into the cyto-
plasm and now intracellular concentrations reached, as
well as the internal targets it interacts with. These results
represent a significant advance in the understanding of the
functioning of this type of AMPs and represent a promising
starting point for the design of new antibiotics.
EXPERIMENTAL PROCEDURES
Peptides
The Bac7 N-terminal fragments Bac71-35 and Bac71-35 with an additional
C-terminal cysteine (Bac71-35Cys) were synthesized as previously described
and their concentrations determined as previously reported (Benincasa
et al., 2004). All peptides, with a purity of at least 95%, were stored in Milli-Q
water at20C until use. The radioactive derivative Bac71-35Alch14C was pre-
pared by alkylating a Bac71-35Cys peptide with
14C-iodocetamide. Amodifica-
tion of a preexisting protocol was used (Creighton, 1997) (see below).
Bac71-35BPA20 was synthesized as an ordinary Bac71-35Cys but substituting
the phenylalanine in position 20 with a 4-benzoyl-L-phenylalanine (Fmoc-4-
benzoyl-L-phenylalanine, Sigma). LL-37 and BMAP-27 were generously pro-
vided by Prof. A. Tossi (University of Trieste).
Bac71-35 Radioactive Labeling
Two milligrams of Bac71-35Cys was dissolved in 300 ml of 10 mM HCl (Carlo
Erba) (prebubbled with N2), divided into five aliquots of 60 ml, and immediately
frozen at 20C until use. All the following procedures were done in the dark.
Twenty-five microliters of 14C-iodoacetamide (IAA) (stock 2 mM14C-IAA in
ethanol, 50–60 mCi/mmol, Biotrend) was diluted in 175 ml of 0.5 M Tris-acetate
(Sigma) and 2mMNa2EDTA (Sigma) (pH 8), named Tris8 (prebubbled with N2).
Then 5 ml of 0.1mMascorbic acid (Sigma) was added, immediately followed by
the first 60 ml aliquot of Bac71-35Cys. The mixture was left at room temperature
under gentle agitation for 30 min in a N2-enriched atmosphere. Another three
Bac71-35Cys aliquots were added every 30 min under the same conditions,
and the third one was immediately followed by 8 ml of nonradioactive 10 mM
IAA (Fluka) dissolved in Tris8 and 2 ml of 1 mM ascorbic acid (Sigma). An addi-
tional aliquot of Bac71-35Cys, followed by 8 ml of nonradioactive 100 mM IAA
dissolved in Tris8 and 2 ml of 1 mM ascorbic acid was then added after
15 min followed by 100 ml of nonradioactive 100 mM IAA in Tris8 and 2 ml of
10 mM ascorbic acid. After 15 min, the mixture was vigorously vortexed for
60 s and then 8 ml of 0.5 M citric acid was added and the mixture was vigor-
ously vortexed for 20 s. The whole reaction mixture was loaded on a desalting
column (Hi-trap desalting, GEHealthcare) and separated by high-performance
liquid chromatography using 100 mM NaCl in Milli-Q water and at 1 ml/min.
Fractions were analyzed by mass spectrometry and the fraction having the
highest content of labeled peptide (Bac71-35Alch
14C) was frozen and stored
for quantification and subsequent uses.
Bacterial Cultures
E. coli BW25113 cells were grown overnight in Mueller-Hinton (MH) broth
(DIFCO) at 37C under agitation. Two hundred microliters of overnight culture
was put in 10 ml of MH broth and incubated at 37C under agitation until an
optical density at 600 nm (OD600) of approximately 0.3 was attained. The bac-
terial suspension was centrifuged (2,000 3 g, 20 min) and the pellet resus-
pended in adequate volumes of MH broth or M9-salt minimal medium with
5 mM glucose and 1% v/v MH broth.
Determination of the Intracellular Concentration of Bac71-35
Midlog phase E. coli BW25113 cells were incubated in MH broth with 10 mM
Bac71-35Alch
14C for 10 min at 37C under agitation. Then, 1 ml of cultureElsevier Ltd All rights reserved
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(6,200 3 g, 10 min), the medium was collected, and the pellet was resus-
pended in 1 ml of fresh medium. In parallel, a third milliliter of the peptide-
treated culture was centrifuged (6,200 3 g, 10 min), the medium was
discarded, and the pellet was resuspended and washed three times in 1 ml
of high-salt phosphate buffer (10 mM Na phosphate buffer, 10 mM MgCl2,
400mMNaCl), to remove the peptide from the bacterial external surface. After
the third washing, the sample was centrifuged (6,2003 g, 10min), the high-salt
phosphate buffer was discarded, and the pellet was resuspended in 1 ml of
fresh MHmedium. The b counter MicroBeta Trilux (Wallac) was used for radio-
activity evaluation, normalizing the result with the OD600 of the samples. Mea-
surements were performed in triplicate for each experiment, mixing 200 ml of
each sample with 500 ml of Opti Phase Supermix (PerkinElmer). Calculation
of the intracellular amount of Bac71-35Alch
14C was carried out by taking into
account the volume of a single BW25113 cell (4.0 fL) (Volkmer and Heine-
mann, 2011), the number of bacteria (8 3 107 colony forming units [cfu]),
and the volume of the sample (200 ml) used for each measurement. The
volume of the pellet was therefore calculated and used to normalize its radio-
activity value. Data were derived from three repetitions of independent exper-
iments. Membrane integrity was evaluated by flow cytometric analysis and
indicated as percentage of propidium iodide-positive cells (Benincasa et al.,
2009). E. coli BW25113 cells (4 3 108 cfu/ml) after treating with the peptide
in MH broth at 37C were diluted to 4 3 106 cfu/ml immediately before
measurements.
DNA-Peptide Interaction Assays
The reaction, as modified from Park et al. (1998), was set up by incubating at
37C for 1 hr 100 ng of linearized pBluescript II KS(+) and different amounts of
each AMP in the presence of 5% glycerol, 10 mM Tris-HCl (pH 7), 1 mMEDTA,
1 mM dithiothreitol, 20 mM KCl, and 50 mg/ml BSA. Samples of the reaction
mixtures were then loaded onto a 1% agarose gel in TAE buffer including
1:10000 Gel red (Biotium) and separated by electrophoresis (90 min, 65 V).
In Vitro Transcription Assay
The commercial kit Riboprobe System–T7 (Promega) was used according to
the instructions for the positive-control samples, but adding each antimicrobial
agent (50 mM) to the reactions. As a negative control, the DNA template was
not added to a reaction. After 60 min of incubation at 37C, RNA was purified
from all samples using TRIzol (Life Technologies). Size and amount of the tran-
scribed RNA were evaluated using a Bioanalyzer 2100 (Agilent) with the kit
Agilent RNA 6000 nano kit (Agilent). Results are the average of three indepen-
dent experiments.
In Vitro Transcription/Translation Assay
The commercial kit S30 T7 High-Yield Protein Expression System (Promega)
was used according to the protocol for the positive-control samples. The pro-
vided plasmid carrying the Renilla luciferase gene is indicated as pLucr. Forty
units of RNase inhibitor (RNase Inhibitor Murine, New England Biolabs) was
added to each reaction, followed by the antimicrobial agent as the last compo-
nent. Samples were incubated at 37C for 1 hr at 1,200 rpm. Then, the pres-
ence of the luciferase was assessed and quantified using both the commercial
kit Renilla Luciferase Assay System (Promega) and 12.5% SDS-PAGE with
Coomassie blue staining. Using the Renilla Luciferase Assay System
(Promega), luminescence was measured by using a Chameleon multitechnol-
ogy plate reader (Hidex) equipped with Mikrowin 2000 software. Results are
the average of three independent experiments.
Incorporation of Radioactive Macromolecular Precursors In Vivo
Midlog phase BW25113 E. coli cells (1.5 3 107 cfu/ml) in M9-salt minimal me-
dium containing 5 mM glucose and 1% v/v MH broth were incubated at 37C.
For leucine incorporation, 7.5 ml of 3H-leucine (1 mCi/ml, PerkinElmer) was
added to 650 ml of bacterial suspension. Eleven minutes after the addition of
the 3H-leucine, Bac71-35 was added to a final concentration of 1 mM. For
uridine incorporation, Bac71-35 was added to a final concentration of 1 mM
and 20 min after the addition of Bac71-35, 4 ml of
3H-uridine (1 mCi/ml,
PerkinElmer) was added to the culture. For thymidine incorporation,
Bac71-35 was added to 650 ml of bacteria to a final concentration of 1 mM.
Twenty minutes after the addition of the Bac71-35, 4 ml of
3H-thymidineChemistry & Biology 21, 1639–164(1 mCi/ml, PerkinElmer) was added to the culture. After sampling at different
times, bacteria were lysed and macromolecules precipitated by incubation
on ice in 10% TCA (with 0.2 mg/ml BSA for protein assay, 0.2 mg/ml salmon
sperm DNA for nucleic acid assay) for at least 60 min, then filtered on
0.22 mm filters (GSTF, Millipore). Radioactivity was measured by scintillation
counting: the filters were dried for 40 min on paper, put into 4 ml of scintillation
fluid (Ecolite[+] liquid scintillation cocktail, MP Biomedicals), and stored for
60 min at room temperature in the dark. The b counter 2200 CA TRI-CARB
liquid scintillation analyzer (Packard) was used, measuring each sample for
10 min. Kanamycin (200 mM), rifampicin (100 mM), and nalidixic acid
(100 mM) were used with identical protocols, respectively, as positive control
for protein, RNA, and DNA synthesis inhibition. Sterile Milli-Q water was
used as negative control for inhibition. Results are the average of three inde-
pendent experiments.
Purification of 70S Ribosomes
E. coli strain MRE600 was grown at 37C to 1.8 OD600 in 3 l of Luria-Bertani
medium. The cells were then cooled on ice, harvested by 20 min of
4,000 3 g centrifugation, and washed with 50 ml of PBS (Biosolve). The cell
pellet was resuspended in 50 ml of 25 mM Tris-HCl (pH 7.5), 10 mM MgCl2,
50 mM NH4Cl, 7 mM b-mercaptoethanol, 8.25% of sucrose supplemented
with one tablet of Complete cocktail protein inhibitors EDTA-free (Roche)
and 0.5 mg/mL lysozyme. After cell lysis by sonication, cell debris was
removed by centrifugation at 28,000 3 g for 30 min in a Beckman centrifuge
with a JA20 rotor. Cleared extract was treated with DNase I (1 mg/l) and centri-
fuged for 3 h 30 min at 184,000 3 g, 4C, in a 70 Ti rotor (Beckman). The
ribosomal pellet was resuspended overnight at 4C in 20 ml of 25 mM Tris-
HCl (pH 7.5), 10 mM MgCl2, 50 mM NH4Cl, and 7 mM b-mercaptoethanol
(RSP) supplemented with Complete cocktail protein inhibitors EDTA-free.
After centrifugation for 20 min at 23,000 3 g and 4C, the supernatant was
layered onto a 18% sucrose cushion in RSP containing 0.5 M NH4Cl and
centrifuged at 184,000 3 g for 3 h at 4C (ultracentrifuge Beckman Optima).
Washing was repeated with 18% sucrose cushion in RSP containing 1 M
NH4Cl. Finally, the ribosomal subunits were dissociated at low Mg
2+ (1 mM
MgCl2) and centrifuged over a two-sucrose cushion, the upper cushion con-
taining 10 ml of 20% sucrose in 50 mM Tris-HCl (pH 7.5), 30 mM KCl,
30 mM NH4Cl, and 0.5 mM MgCl2 and the lower one 5 ml of 30% sucrose in
50 mM Tris-HCl (pH 7.5), 30 mM KCl, 30 mM NH4Cl, and 13 mM MgCl2. After
6 h 30 min of ultracentrifugation at 118,0003 g and 4C, the reassociated 70S
ribosomal pellet was resuspended in 2 ml RSP and dialyzed into RSP contain-
ing 50% glycerol. The ribosome concentration was determined by UV absor-
bance at 260 nm (1 A260 unit = 25 pmol/ml). The quality of the ribosomes was
controlled (1) by SDS-PAGE, (2) in the poly(U)-dependent poly(Phe) synthesis
assay, and (3) by centrifugation in the 15% to 35% sucrose gradient, as previ-
ously described (Graham and Rickwood, 1997).
Ribosome-Bac71-35 Cosedimentation Assay
One micromolar purified 70S ribosomes were incubated at 4C for 30 min with
increasing concentrations of Bac7 peptide (0.5–30 mM) in a total volume of
150 ml binding buffer (20 mM HEPES-KOH, 100 mM NH4OAc, 20 mM MgCl2,
1 mM TCEP [pH 7.4]). Samples were cleared by centrifugation (16,100 3 g,
10 min, 4C). Supernatants were transferred into 1.5 ml Eppendorf tubes
and centrifuged in a Beckman TL100 ultracentrifuge using a TLA100.3 rotor
(8,6000 3 g, 128 min, 4C). Ribosomal pellets were washed twice with
200 ml of ice-cold binding buffer and dissolved in 20 ml of 23 Laemmli buffer.
Proteins from each sample were separated by using 12% NuPAGE Bis-Tris
Precast Gels in MES buffer (Life Technologies). After electrophoresis, the pro-
teins were transferred to a low-fluorescent polyvinylidenedifluoride membrane
(GE Healthcare) and treated according to the manufacturer’s instructions.
Blots were blocked immediately after transfer in 5% (w/v) ECL Advance block-
ing reagent (GE Healthcare) in 13 PBS with 0.3% (v/v) Tween-20 for 2 hr at
room temperature with agitation or overnight at 4C. Bac71-35 peptide was de-
tected with anti-Bac7 primary serum used at dilution 1:200 (1 h, RT). The blots
were washed several times before incubation with the secondary antibody
(ECL Plex goat antirabbit IgG-Cys5; GE Healthcare) at a dilution of 1:2,000
for 1 h. The membranes were washed before drying and scanned for Cy5 on
the Pharos FX Molecular Imager System (Bio-Rad). Imaging was performed
using a 635-nm laser with a 695-nm band-pass filter. The images were then7, December 18, 2014 ª2014 Elsevier Ltd All rights reserved 1645
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ware (Bio-Rad) according to the manufacturer’s instructions. To quantify
and normalize each band (Adam et al., 2011), we used the relative volume in-
tensity of the band that corresponded to the total signal intensity within a
defined area. Background was subtracted from obtained values. Relative vol-
ume intensities of immunoblot bands are shown as arbitrary units. The quantity
of loaded ribosome was controlled by western blot membrane staining with
Ponceau red.
UV Crosslinking
One micromolar ribosomes were incubated with 10 mM Bac71-35 BPA20 for
30 min at 8C with gentle agitation in the presence of 20 mM HEPES-KOH,
100 mM CH3COONH4, 20 mM MgCl2, and 1 mM TCEP (pH 7.4). The reaction
mix was subsequently exposed to UV light (l = 365 nm) for 5 min at 8C in a
quartz cuvette (Amersham, l = 0.2 cm). The crosslinked proteins were revealed
by 16% tricine SDS-PAGE and western blot using an anti-Bac7 antibody.
Statistical Analysis
Data obtained were subjected to computer-assisted analysis using Graph Pad
Instat 3 and statistical significance was assumed at p < 0.05 (ANOVA, Tukey-
Kramer posttest). Error bars represent SD.
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